CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: 020745

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-745

Glaxo Wellcome, Inc.
Attention: Sara Armentrout
Five Moore Drive
P.O. Box 13358
Research Triangle Park, NC 27709

FEB 26 1998

Dear Ms. Armentrout:

Please refer to your new drug application dated July 2, 1996, received July 16, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for nonprescription Zantac® 75 EFFERdose® (ranitidine hydrochloride) Effervescent Tablets, 75 mg.

We acknowledge receipt of your submissions dated August 25 and October 20, 1997. Your submission of August 25, 1997 constituted a complete response to our July 8, 1997 action letter. The User Fee goal date is February 26, 1998.

This new drug application provides for Zantac® 75 EFFERdose® (ranitidine hydrochloride) Effervescent Tablets as an alternate dosage form for nonprescription ranitidine hydrochloride.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the labeling included in the submission dated August 25, 1997, with the revisions listed below. Accordingly, the application is approved effective on the date of this letter. The revisions, as discussed with you in a February 24, 1998 telephone conversation, are as follows:

1. Delete the word "quickly" from the second sentence of the first bullet statement on the front of the package insert.

2. Within 6 months or at the next printing of the labeling, whichever comes first:

   a. Revise the directions to state "Dissolve 1 EFFERdose® tablet completely in a full glass of water."

   b. Add a section titled "Tips for Managing Heartburn" with the following bullet statements to the package insert:

      - Do not lie flat or bend over soon after eating.

- Do not eat late at night, or just before bedtime.
- Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty, and fried foods, chocolate, caffeine, alcohol, and even some fruits and vegetables.
- Eat slowly and do not eat big meals.
- If you are overweight, lose weight.
- If you smoke, stop or cut down smoking.
- Raise the head of your bed.
- Avoid wearing tight clothing around your stomach.

These revisions are the terms of the NDA approval. Marketing the product before making the revisions, exactly as requested, in the product's final printed labeling (FPL) may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-745. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required. In addition, revision of the labeling may be necessary when the February 27, 1997 Federal Register Notice "Over-the-Counter Human Drugs; Proposed Labeling Requirements" [62 FR 9023] becomes final.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

In addition, please submit four copies of the introductory promotional material that you propose to use for this product. Please include all product labeling. All proposed materials should be in draft or mock-up form, not final print. Please submit one copy to the Division of Gastrointestinal and Coagulation Drug Products, one copy to the Division of Over-the-Counter Drug Products, and two copies directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

In line with Center for Drug Evaluation and Research policy, oversight of this application is being transferred to the Division of Over-the-Counter Drug Products. If you have any questions, please contact Sakineh Walther, Regulatory Health Project Manager, at (301) 827-2248.

Sincerely,

/S/

Lilia Talarico, M.D.
Director
Division of Gastrointestinal and
Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

/S/

Debra Bowen, M.D.
Director
Division of Over-The-Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL